MLLT3 and acute myeloid leukemia: In vivo, however, while the deletion of CXCR4 in AML MLL-AF9+ HSPCs prolonged leukemic mouse survival, deletion of CXCL12 within the AML microenvironment did not alter the development and progression of the disease (166).